Echo Therapeutics Financials

Echo Therapeutics Stock Summary

Echo Therapeutics competes with National Beverage, Jutal Offshore, Zevia Pbc, BioNTech, and Molson Coors. Echo Therapeutics, Inc. engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. The company was founded in 1989 and is headquartered in Iselin, New Jersey. Echo Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 19 people.

Echo Therapeutics Key Financial Ratios

Generally speaking, Echo Therapeutics' financial ratios allow both analysts and investors to convert raw data from Echo Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Echo Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Echo Therapeutics reports annually and quarterly.

Echo Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Echo Therapeutics's current stock value. Our valuation model uses many indicators to compare Echo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Echo Therapeutics competition to find correlations between indicators driving Echo Therapeutics's intrinsic value. More Info.Echo Therapeutics is one of the top stocks in return on equity category among related companies. It is one of the top stocks in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Echo Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Echo Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Echo Therapeutics' earnings, one of the primary drivers of an investment's value.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

If you are still planning to invest in Echo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Echo Therapeutics' history and understand the potential risks before investing.